Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. (Q51620290)

8 April 2018

title

Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. (English)

1 reference

8 April 2018

genome-wide association study

main subject

0 references

0 references

1 reference

parkinsonian syndrome

1 reference

Ana Alkelai

1

1 reference

8 April 2018

Lior Greenbaum

2

1 reference

8 April 2018

Amihai Rigbi

3

1 reference

8 April 2018

Kyra Kanyas

4

1 reference

8 April 2018

Bernard Lerer

5

1 reference

8 April 2018

publication date

13 August 2009

1 reference

8 April 2018

published in

Psychopharmacology

1 reference

8 April 2018

volume

206

1 reference

8 April 2018

issue

3

1 reference

8 April 2018

page(s)

491-499

1 reference

8 April 2018

describes a project that uses

genome-wide association study

1 reference

Antipsychotic Drug-Induced Movement Disorders

inferred from title

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-009-1627-Z

Instrumental motor predictors of neuroleptic-induced parkinsonism in newly medicated schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-009-1627-Z

An instrumental study of the relationship between extrapyramidal signs and psychosis in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-009-1627-Z

Parkinsonism in neuroleptic-naive schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-009-1627-Z

Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-009-1627-Z

21 January 2018

Neuroleptic intolerance

1 reference

https://api.crossref.org/works/10.1007%2FS00213-009-1627-Z

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-009-1627-Z

Rescuing Z+ agrin splicing in Nova null mice restores synapse formation and unmasks a physiologic defect in motor neuron firing

21 January 2018

1 reference

12 December 2020

Expression of the guanine nucleotide exchange factor, mr-gef, is regulated during the differentiation of specific subsets of telencephalic neurons

1 reference

12 December 2020

Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia

1 reference

12 December 2020

Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology

1 reference

12 December 2020

Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment

1 reference

12 December 2020

Interaction between fidgetin and protein kinase A-anchoring protein AKAP95 is critical for palatogenesis in the mouse

1 reference

12 December 2020

Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia

1 reference

12 December 2020

Principal components analysis corrects for stratification in genome-wide association studies

1 reference

12 December 2020

Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study

1 reference

12 December 2020

Pivotal role of early B-cell factor 1 in development of striatonigral medium spiny neurons in the matrix compartment

1 reference

12 December 2020

Functionality of intergenic transcription: an evolutionary comparison

1 reference

12 December 2020

Ebf gene function is required for coupling neuronal differentiation and cell cycle exit

1 reference

12 December 2020

Genomewide association studies: history, rationale, and prospects for psychiatric disorders

1 reference

12 December 2020

Abnormal movements in never-medicated Indian patients with schizophrenia.

1 reference

12 December 2020

Genome-wide association analyses suggested a novel mechanism for smoking behavior regulated by IL15

1 reference

12 December 2020

Drug-induced parkinsonism in the elderly

1 reference

12 December 2020

Therapeutic implications of differential effects of new phenothiazine compounds

1 reference

12 December 2020

Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients

1 reference

12 December 2020

The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies

1 reference

12 December 2020

Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms

1 reference

12 December 2020

The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel.

1 reference

12 December 2020

Genomewide association for schizophrenia in the CATIE study: results of stage 1

1 reference

12 December 2020

Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication.

1 reference

12 December 2020

Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study

1 reference

12 December 2020

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

1 reference

12 December 2020

SLCO1B1 variants and statin-induced myopathy--a genomewide study

1 reference

12 December 2020

Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment

1 reference

12 December 2020

Pharmacogenomics in schizophrenia: the quest for individualized therapy.

1 reference

12 December 2020

Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders.

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients.

1 reference

12 December 2020

Biperiden in the treatment of phenothiazine-induced extrapyramidal reactions

1 reference

12 December 2020

Principal component analysis of genetic data

1 reference

12 December 2020

Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis

1 reference

12 December 2020

Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients

1 reference

12 December 2020

Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia

1 reference

12 December 2020

The mouse fidgetin gene defines a new role for AAA family proteins in mammalian development

1 reference

12 December 2020

Parkinson's disease: from monogenic forms to genetic susceptibility factors

1 reference

12 December 2020

A survey of drug-induced extrapyramidal reactions

1 reference

12 December 2020

Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis

1 reference

12 December 2020

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

1 reference

12 December 2020

Significance and meaning of neurological signs in schizophrenia: two decades later

1 reference

12 December 2020

PLINK: a tool set for whole-genome association and population-based linkage analyses

1 reference

12 December 2020

Atypical Antipsychotics and Parkinsonism

1 reference

12 December 2020

Pathophysiology of antipsychotic drug-induced movement disorders.

1 reference

12 December 2020

Regulation of an intergenic transcript controls adjacent gene transcription in Saccharomyces cerevisiae.

1 reference

12 December 2020

Ventral mesencephalon-enriched genes that regulate the development of dopaminergic neurons in vivo.

1 reference

12 December 2020

Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors

1 reference

12 December 2020

Neurological complications of psychiatric drugs: clinical features and management

1 reference

12 December 2020

Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

The use of pedigree, sib-pair and association studies of common diseases for genetic mapping and epidemiology

1 reference

12 December 2020

Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population

1 reference

12 December 2020

Pharmacogenomic genome-wide association studies: lessons learned thus far.

1 reference

12 December 2020

Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.

1 reference

12 December 2020

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

12 December 2020

10.1007/S00213-009-1627-Z

Identifiers

DOI

1 reference

8 April 2018

1 reference

8 April 2018